BioStem wins Nasdaq uplisting, expanding capital access for regenerative medicine push
What's the deal? BioStem Technologies, a Pompano Beach, Florida-based regenerative medicine company, said NasdaqDealroom has a profile for this one. Try Dealroom → has approved its common stock for listing on The Nasdaq Capital Market. Its shares are expected to begin trading on August 7, 2026, under the unchanged ticker symbol "BSEM."
Why now? The company had traded over the counter (OTC: BSEM) before the uplisting. Chairman and chief executive officer Jason Matuszewski said the move reflects "the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy."
What's the endgame? BioStem develops, manufactures, and commercialises perinatal tissue allograft products used by clinicians across a range of specialties. It leverages proprietary BioRetain, CryoTek, and SteriTek processing technologies, with a portfolio spanning the Neox, Clarix, VENDAJE, and American Amnion product lines.
What does it mean for shareholders? The company said its stakeholders need not take any action as a result of the listing. Matuszewski said the company expects the uplisting to "expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent."
The signal: Moving from OTC markets to Nasdaq is a step up in visibility and liquidity that regenerative medicine companies often pursue to broaden their investor base as they scale. For BioStem, the listing signals a bid to convert operational progress into wider capital access — provided it maintains Nasdaq's continued listing standards.
Read more: AP News
Image credit: pingnews.com
